<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11291">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586469</url>
  </required_header>
  <id_info>
    <org_study_id>111258</org_study_id>
    <nct_id>NCT00586469</nct_id>
  </id_info>
  <brief_title>A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk</brief_title>
  <official_title>Observer-blind, Post-Marketing Study to Compare the Safety and Immunogenicity of Fluviral® Trivalent Split Virion Influenza Vaccine (2007-2008 Season) Made With New vs. Aged Bulk Material, in Adults Ranging in Age From 18 to 60 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccination is currently the most effective means of controlling influenza and preventing
      its complications and mortality in persons at risk.

      Once a year, a meeting of World Health Organization (WHO) experts takes place, leading to a
      recommendation on the influenza A and B strains that should be used for the production of
      vaccine for the coming influenza season. For the strains which do not change from the
      previous year, the vaccine can be formulated from the old mono bulk from the previous year.

      Bulks as old as 12 months may be blended to make trivalent inactivated vaccine (TIV) under
      the current Canadian and US licenses. This study is conducted to evaluate safety and
      immunogenicity of Fluviral vaccines made with the aged bulk material compared with the new
      bulk material. This protocol posting has been updated in order to comply with the FDA
      Amendment Act, Sept 2007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Anti-H3 and B Strains</measure>
    <time_frame>At Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>GMTs for H1 strain is addressed as a secondary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of the H1 Strain and the GMT of the H3 and B Strains</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>The table contains GMTs of the H1 strains at Day 0 &amp; 21 and of the H3 and B strains at Day 0 (values at Day 21 for H3 and B strains were primary outcome measures)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Seroconverted.</measure>
    <time_frame>At Day 21.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The table shows the number of participants who have either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer &gt;= 1:40 or a prevaccination titer &gt;= 1:10 and at least a 4-fold increase in post-vaccination titer, at Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Participants.</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>The table presents the number of participants with a serum haemagglutination inhibition (HI) titer &gt;= 1:40 that usually is accepted as indicating protection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factors Defined as the Fold Increase in Serum HI GMTs Post-vaccination for Influenza Antigen H1N1</measure>
    <time_frame>At Day 21 compared to Day 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion factors are defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0, at Day 21. This table presents the SCF for the H1 strain. The SCF for the other strains are addressed in the next table.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Fold Increase in Anti-HI GMTs for Influenza Antigens H3 and B</measure>
    <time_frame>At Day 21 compared to Day 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>The fold increase in anti-HI GMTs for influenza antigen H1 is presented in the previous table.
The &quot;fold increase&quot; corresponds to the Unit of Measure &quot;Factor.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited Local Symptoms</measure>
    <time_frame>During the 4-day follow up period following vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Solicited General Symptoms</measure>
    <time_frame>During the 4-day period following each vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed include bronchospasm, chills, cough, fatigue, fever, headache, joint pain at other location, muscle aches, red eyes, sore throat, and swelling of the face</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Unsolicited Adverse Events (AE).</measure>
    <time_frame>During the 21-day period following each vaccination.</time_frame>
    <safety_issue>No</safety_issue>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting Serious Adverse Events (SAE)</measure>
    <time_frame>Within 21 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1000</enrollment>
  <condition>Influenza</condition>
  <condition>Influenza Vaccines</condition>
  <arm_group>
    <arm_group_label>Old Bulk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group receives a full dose of Fluviral made from aged bulk material</description>
  </arm_group>
  <arm_group>
    <arm_group_label>New Bulk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group receives a full dose of Fluviral made from new material</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluviral</intervention_name>
    <description>One dose, Intramuscular injection</description>
    <arm_group_label>Old Bulk</arm_group_label>
    <arm_group_label>New Bulk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol should be enrolled in the study.

          -  Male and female adults, 18 to 60 years.

          -  Written informed consent obtained from the subject.

          -  If the subject is female, she must be of non-childbearing potential or if she is of
             childbearing potential, she must practice adequate contraception for 30 days prior to
             vaccination, have a negative pregnancy test and continue such precautions for the
             duration of the study.

        Exclusion Criteria:

          -  Acute disease at the time of enrollment.

          -  Any confirmed or suspected immunosuppressive condition

          -  Presence of blood dyscrasias, including hemaglobinopathies and myelo- or
             lymphoproliferative disorder.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  A history of any demyelinating disease including Guillain-Barré syndrome.

          -  Presence of an active neurological disorder.

          -  Any significant disorder of coagulation that increases the risk of intramuscular
             injections or treatment with coumadin derivatives or heparin.

          -  Receipt of an influenza vaccine within 6 months prior to study enrollment.

          -  Administration of any vaccines within 30 days prior to study enrollment or during the
             study period.

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the vaccination or planned use during the
             study period.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the administration of the study vaccine or planned during the study.

          -  Any known or suspected allergy to any constituent of Fluviral and/or a history of
             anaphylactic type reaction to consumption of eggs, and/or reactions to products
             containing mercury.

          -  A history of severe adverse reaction to a previous influenza vaccination.

          -  Lactating/nursing female.

          -  Any condition which, in the opinion of the investigator, prevents the subject from
             participation in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>July 11, 2013</lastchanged_date>
  <firstreceived_date>December 21, 2007</firstreceived_date>
  <firstreceived_results_date>January 14, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Old Bulk</title>
          <description>This group received a full dose of Fluviral made from aged bulk material</description>
        </group>
        <group group_id="P2">
          <title>New Bulk</title>
          <description>This group received a full dose of Fluviral made from new material</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="500"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="500"/>
                <participants group_id="P2" count="499"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Old Bulk</title>
          <description>This group received a full dose of Fluviral made from aged bulk material</description>
        </group>
        <group group_id="B2">
          <title>New Bulk</title>
          <description>This group received a full dose of Fluviral made from new material</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="500"/>
                <measurement group_id="B2" value="500"/>
                <measurement group_id="B3" value="1000"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40.0" spread="12.08"/>
                <measurement group_id="B2" value="40.1" spread="12.01"/>
                <measurement group_id="B3" value="40.1" spread="12.04"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="296"/>
                <measurement group_id="B2" value="280"/>
                <measurement group_id="B3" value="576"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="204"/>
                <measurement group_id="B2" value="220"/>
                <measurement group_id="B3" value="424"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Anti-H3 and B Strains</title>
        <description>GMTs for H1 strain is addressed as a secondary endpoint</description>
        <time_frame>At Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-To-Protocol cohort for immunogenicity, including subjects for whom results were available for that particular timepoint and who were not eliminated due to exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Bulk</title>
            <description>This group received a full dose of Fluviral made from aged bulk material</description>
          </group>
          <group group_id="O2">
            <title>New Bulk</title>
            <description>This group received a full dose of Fluviral made from new material</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="298"/>
                  <measurement group_id="O2" value="291"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) of Anti-H3 and B Strains</title>
            <description>GMTs for H1 strain is addressed as a secondary endpoint</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-H3N2 antibody GMT</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="369.6" lower_limit="323.4" upper_limit="422.4"/>
                  <measurement group_id="O2" value="331.2" lower_limit="288.8" upper_limit="379.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-B antibody GMT</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="269.6" lower_limit="241.6" upper_limit="300.9"/>
                  <measurement group_id="O2" value="245.0" lower_limit="216.7" upper_limit="276.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of the H1 Strain and the GMT of the H3 and B Strains</title>
        <description>The table contains GMTs of the H1 strains at Day 0 &amp; 21 and of the H3 and B strains at Day 0 (values at Day 21 for H3 and B strains were primary outcome measures)</description>
        <time_frame>At Days 0 and 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-To-Protocol cohort for immunogenicity, including subjects for whom results were available for that particular timepoint and who were not eliminated due to exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Bulk</title>
            <description>This group received a full dose of Fluviral made from aged bulk material</description>
          </group>
          <group group_id="O2">
            <title>New Bulk</title>
            <description>This group received a full dose of Fluviral made from new material</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="298"/>
                  <measurement group_id="O2" value="292"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (GMTs) of the H1 Strain and the GMT of the H3 and B Strains</title>
            <description>The table contains GMTs of the H1 strains at Day 0 &amp; 21 and of the H3 and B strains at Day 0 (values at Day 21 for H3 and B strains were primary outcome measures)</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Anti-H1N1 antibody GMT at Day 0 (n=297, 292)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15.1" lower_limit="13.1" upper_limit="17.4"/>
                  <measurement group_id="O2" value="15.7" lower_limit="13.6" upper_limit="18.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-H1N1 antibody GMT at Day 21 (n=298, 291)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="188.1" lower_limit="163.6" upper_limit="216.4"/>
                  <measurement group_id="O2" value="169.9" lower_limit="147.3" upper_limit="196.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-H3N2 antibody GMT at Day 0 (n=297, 292)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30.4" lower_limit="25.8" upper_limit="35.9"/>
                  <measurement group_id="O2" value="35.7" lower_limit="30.1" upper_limit="42.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-B antibody GMT at Day 0 (n=297, 292)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.3" lower_limit="25.3" upper_limit="33.9"/>
                  <measurement group_id="O2" value="30.0" lower_limit="25.8" upper_limit="34.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Seroconverted.</title>
        <description>The table shows the number of participants who have either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer &gt;= 1:40 or a prevaccination titer &gt;= 1:10 and at least a 4-fold increase in post-vaccination titer, at Day 21.</description>
        <time_frame>At Day 21.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-To-Protocol cohort for immunogenicity, including subjects for whom results were available for that particular timepoint and who were not eliminated due to exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Bulk</title>
            <description>This group received a full dose of Fluviral made from aged bulk material</description>
          </group>
          <group group_id="O2">
            <title>New Bulk</title>
            <description>This group received a full dose of Fluviral made from new material</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="297"/>
                  <measurement group_id="O2" value="291"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Seroconverted.</title>
            <description>The table shows the number of participants who have either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer &gt;= 1:40 or a prevaccination titer &gt;= 1:10 and at least a 4-fold increase in post-vaccination titer, at Day 21.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-H1N1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="218"/>
                  <measurement group_id="O2" value="197"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-H3N2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="212"/>
                  <measurement group_id="O2" value="187"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-B</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="205"/>
                  <measurement group_id="O2" value="185"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Participants.</title>
        <description>The table presents the number of participants with a serum haemagglutination inhibition (HI) titer &gt;= 1:40 that usually is accepted as indicating protection.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-To-Protocol cohort for immunogenicity, including subjects for whom results were available for that particular timepoint and who were not eliminated due to exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Bulk</title>
            <description>This group received a full dose of Fluviral made from aged bulk material</description>
          </group>
          <group group_id="O2">
            <title>New Bulk</title>
            <description>This group received a full dose of Fluviral made from new material</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="298"/>
                  <measurement group_id="O2" value="292"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Seroprotected Participants.</title>
            <description>The table presents the number of participants with a serum haemagglutination inhibition (HI) titer &gt;= 1:40 that usually is accepted as indicating protection.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-H1N1 at Day 0 (n=297, 292)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="90"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-H1N1 at Day 21 (n=298, 291)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="276"/>
                  <measurement group_id="O2" value="266"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-H3N2 at Day 0 (n=297, 292)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="149"/>
                  <measurement group_id="O2" value="154"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-H3N2 at Day 21 (n=298, 291)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="293"/>
                  <measurement group_id="O2" value="286"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-B antibody GMT at Day 0 (n=297, 292)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="144"/>
                  <measurement group_id="O2" value="150"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-B antibody GMT at Day21 (n=298, 291)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="295"/>
                  <measurement group_id="O2" value="285"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factors Defined as the Fold Increase in Serum HI GMTs Post-vaccination for Influenza Antigen H1N1</title>
        <description>Seroconversion factors are defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0, at Day 21. This table presents the SCF for the H1 strain. The SCF for the other strains are addressed in the next table.</description>
        <time_frame>At Day 21 compared to Day 0</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-To-Protocol cohort for immunogenicity, including subjects for whom results were available for that particular timepoint and who were not eliminated due to exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Bulk</title>
            <description>This group received a full dose of Fluviral made from aged bulk material</description>
          </group>
          <group group_id="O2">
            <title>New Bulk</title>
            <description>This group received a full dose of Fluviral made from new material</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="297"/>
                  <measurement group_id="O2" value="291"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seroconversion Factors Defined as the Fold Increase in Serum HI GMTs Post-vaccination for Influenza Antigen H1N1</title>
            <description>Seroconversion factors are defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0, at Day 21. This table presents the SCF for the H1 strain. The SCF for the other strains are addressed in the next table.</description>
            <units>Factor</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12.5"/>
                  <measurement group_id="O2" value="10.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Fold Increase in Anti-HI GMTs for Influenza Antigens H3 and B</title>
        <description>The fold increase in anti-HI GMTs for influenza antigen H1 is presented in the previous table.
The &quot;fold increase&quot; corresponds to the Unit of Measure &quot;Factor.&quot;</description>
        <time_frame>At Day 21 compared to Day 0</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the According-To-Protocol cohort for immunogenicity, including subjects for whom results were available for that particular timepoint and who were not eliminated due to exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Bulk</title>
            <description>This group received a full dose of Fluviral made from aged bulk material</description>
          </group>
          <group group_id="O2">
            <title>New Bulk</title>
            <description>This group received a full dose of Fluviral made from new material</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="297"/>
                  <measurement group_id="O2" value="291"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Fold Increase in Anti-HI GMTs for Influenza Antigens H3 and B</title>
            <description>The fold increase in anti-HI GMTs for influenza antigen H1 is presented in the previous table.
The &quot;fold increase&quot; corresponds to the Unit of Measure &quot;Factor.&quot;</description>
            <units>Factor</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Anti-H3N2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="12.1"/>
                  <measurement group_id="O2" value="9.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Anti-B</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.2"/>
                  <measurement group_id="O2" value="8.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
        <time_frame>During the 4-day follow up period following vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Bulk</title>
            <description>This group received a full dose of Fluviral made from aged bulk material</description>
          </group>
          <group group_id="O2">
            <title>New Bulk</title>
            <description>This group received a full dose of Fluviral made from new material</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="500"/>
                  <measurement group_id="O2" value="500"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Solicited Local Symptoms</title>
            <description>Solicited local symptoms assessed include pain, redness and swelling.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="271"/>
                  <measurement group_id="O2" value="290"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88"/>
                  <measurement group_id="O2" value="97"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="63"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include bronchospasm, chills, cough, fatigue, fever, headache, joint pain at other location, muscle aches, red eyes, sore throat, and swelling of the face</description>
        <time_frame>During the 4-day period following each vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Bulk</title>
            <description>This group received a full dose of Fluviral made from aged bulk material</description>
          </group>
          <group group_id="O2">
            <title>New Bulk</title>
            <description>This group received a full dose of Fluviral made from new material</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="500"/>
                  <measurement group_id="O2" value="500"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Solicited General Symptoms</title>
            <description>Solicited general symptoms assessed include bronchospasm, chills, cough, fatigue, fever, headache, joint pain at other location, muscle aches, red eyes, sore throat, and swelling of the face</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Bronchospasm</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cough</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="113"/>
                  <measurement group_id="O2" value="113"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Axillary fever &gt;= 37.5° Celsius (C)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="110"/>
                  <measurement group_id="O2" value="101"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Joint pain at other location</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Muscle aches</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="141"/>
                  <measurement group_id="O2" value="138"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Red eyes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sore throat</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling of the face</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Unsolicited Adverse Events (AE).</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
        <time_frame>During the 21-day period following each vaccination.</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the Total Vaccinated Cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Old Bulk</title>
            <description>This group received a full dose of Fluviral made from aged bulk material</description>
          </group>
          <group group_id="O2">
            <title>New Bulk</title>
            <description>This group received a full dose of Fluviral made from new material</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="500"/>
                  <measurement group_id="O2" value="500"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Unsolicited Adverse Events (AE).</title>
            <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="127"/>
                  <measurement group_id="O2" value="129"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting Serious Adverse Events (SAE)</title>
        <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
        <time_frame>Within 21 days after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Old Bulk</title>
            <description>This group received a full dose of Fluviral made from aged bulk material</description>
          </group>
          <group group_id="O2">
            <title>New Bulk</title>
            <description>This group received a full dose of Fluviral made from new material</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="500"/>
                  <measurement group_id="O2" value="500"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Reporting Serious Adverse Events (SAE)</title>
            <description>An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any SAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fatal SAE</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Old Bulk</title>
          <description>This group received a full dose of Fluviral made from aged bulk material</description>
        </group>
        <group group_id="E2">
          <title>New Bulk</title>
          <description>This group received a full dose of Fluviral made from new material</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19"/>
                <counts group_id="E2" subjects_affected="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="500"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
